Cargando…
Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection
We present the case of a 21-month-old girl with two rare and life-threatening conditions, atypical haemolytic uraemic syndrome (aHUS) and haemophagocytic lymphohistiocytosis (HLH), triggered by a cytomegalovirus (CMV) infection. Soon after admission, the girl became anuric and required continuous ve...
Autores principales: | Fraga-Rodriguez, Gloria M, Brió-Sanagustin, Sonia, Turón-Viñas, Eulalia, Dixon, Bradley P, Carreras-González, Eduardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Case Reports
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534672/ https://www.ncbi.nlm.nih.gov/pubmed/28446488 http://dx.doi.org/10.1136/bcr-2016-219065 |
Ejemplares similares
-
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017) -
Outcome of atypical haemolytic uraemic syndrome relapse after
eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020) -
Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)